LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Glycated Hemoglobin Screening Reveals Undiagnosed Diabetes

By LabMedica International staff writers
Posted on 15 Oct 2020
Image: Glycated Hemoglobin (HbA1c) Screening Reveals Undiagnosed Diabetes (Photo courtesy of Diabetes.co.uk).
Image: Glycated Hemoglobin (HbA1c) Screening Reveals Undiagnosed Diabetes (Photo courtesy of Diabetes.co.uk).
Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, and unexplained weight loss.

Threshold for diagnosis of diabetes is based on the relationship between results of glucose tolerance tests, fasting glucose or glycated hemoglobin (HbA1c) and complications such as retinal problems. HbA1c has the advantages that fasting is not required and results are more stable but has the disadvantage that the test is more costly than measurement of blood glucose.

Scientists at the University of Exeter Medical School (Exeter, UK) analyzed data from 216,644 UK Biobank participants with primary care records available and an HbA1c measured at recruitment. They defined participants without a diagnosis of diabetes at recruitment as those who did not self-report diabetes or had no indications of diabetes in their primary care records before recruitment. For participants with undiagnosed diabetes, the team calculated the time that it took to receive a clinical diagnosis in their primary care records, defined as the first diagnosis code for diabetes, an HbA1c of at least 48 mmol/mol (6.5%), or a prescription for glucose-lowering medication.

The investigators reported that within the cohort, 2,022, or 1%, had undiagnosed diabetes on screening by HbA1c. Compared with those with an HbA1c of less than 48 mmol/mol, individuals with an HbA1c of at least 48 mmol/mol on screening were statistically older (mean age, 61 years versus 58 years) had obesity (mean BMI, 31 kg/m2 versus 26.6 kg/m2) and were more frequently men versus women (60% versus 45%). Of the 82% of participants with undiagnosed diabetes who had primary care records covering the period after recruitment, median time to clinical diagnosis was 2.3 years, with 23% not diagnosed at 5-year follow-up.

Katie Young, PhD, a postdoctoral research associate and lead author of the study, said, “The fact that, on average, screening identified these people two years earlier than their doctors was quite surprising to us and suggests that screening could improve patient outcomes by allowing lifestyle interventions and diabetes treatment to begin much earlier.” The study was presented at the European Association for the Study of Diabetes virtual annual meeting held 21-25, September, 2020.

Related Links:
University of Exeter Medical School

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more